摘要
目的探讨γ-氨基丁酸(GABA)治疗前后哮喘患儿血浆P物质(SP)和降钙素基因相关肽(CGRP)含量的变化。方法 75例哮喘患儿随机分为GABA治疗组(36例)和对照组(39例),两组患儿均给予哮喘常规治疗。治疗组在常规治疗的基础上给予GABA口服(每日25～30 mg/kg)。采用酶联免疫吸附法(ELISA)测定患儿治疗前、缓解后血浆SP、CGRP的含量。结果两组患儿治疗前血浆SP、CGRP含量差异无统计学意义(P>0.05);哮喘缓解后治疗组血浆SP、CGRP含量分别为57±15 pg/mL、23±10 pg/mL,显著低于对照组(分别为127±12 pg/mL、42±8 pg/mL),差异有统计学意义(P<0.01)。两组哮喘缓解后血浆SP、CGRP含量均较治疗前明显下降,差异有统计学意义(P<0.01)。哮喘患儿血浆SP与CGRP含量呈显著正相关(r=0.792,P<0.01)。结论GABA可抑制小儿哮喘急性发作期血浆SP、CGRP的释放。
Objective To study the changes in plasma substance P （SP） and calcitonin gene-related peptide （CGRP） levels in children with acute asthma before and after gamma-aminobutyricacid （GABA） treatment. Methods Seventy-five children with asthma were randomly assigned to GABA treatment （ n = 36） and control groups （ n = 39）. Both groups were given conventional treatment for asthma. Besides the conventional treatment, the treatment group was administered with oral GABA （ 25 - 30 mg/kg· d）. Plasma content of SP and CGRP was measured using ELISA before treatment and after remission. Results There were no significant differences in plasma content of SP and CGRP between the GABA treatment and control groups （P 〉 0.05 ） before treatment. Plasma content of SP and CGRP in the GABA treatment group was significantly lower than the control group （ SP： 57 ± 15 pg/mL vs 127 ± 12 pg/mL; CGRP： 23 ± 10 pg,/mL vs 42 ± 8 pg/mL） after remission （P 〈 0.01 ）. Plasma content of SP and CGRP after remission was significantly lower than before treatment （P 〈0.01 ）in both groups. There was a significantly positive correlation between plasma SP and CGRP content in asthmatic children （ r = 0. 792, P 〈 0.01 ）. Conclusions GABA can significantly decrease plasma levels of SP and CGRP in children suffering from acute asthma.
出处
《中国当代儿科杂志》
CAS
CSCD
北大核心
2013年第2期102-104,共3页
Chinese Journal of Contemporary Pediatrics
基金
滨州市科技发展计划(政策引导类)项目(编号:2011ZC0930)
关键词
γ--氨基丁酸
P物质
降钙素基因相关肽
哮喘
儿童
Gamma-aminobutyricacid
Substance P
Calcitonin gene-related peptide
Asthma
Child
